Role of Bcl-2, p53, and Ki-67 expression in basal cell carcinoma and their association with aggressive and non-aggressive histological phenotypes

Raúl Gerardo Mendez-Flores1, Diana Emilia Martínez-Fernández1, Diego Ernesto Vega-De la Torre1, Marianela Zambrano-Román2, José Francisco Muñoz-Valle2, Mario Gaston Toledo-Lelevier1, Elizabeth Guevara-Gutiérrez2, Marisol Ramírez-Padilla2, Emmanuel Valdés-Alvarado2

1Department of Dermatology, Civil Hospital of Guadalajara “Fray Antonio Alcalde”, Guadalajara, Mexico
2Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico
3Department of Pathology, Civil Hospital of Guadalajara “Fray Antonio Alcalde”, Guadalajara, Mexico
4Department of Dermatology, Instituto Dermatológico de Jalisco “Dr. José Barba Rubio”, Secretaría de Salud Jalisco, Zapopan Jalisco, México

Adv Dermatol Allergol 2022; XXXIX (3): 517–523
DOI: https://doi.org/10.5114/ada.2022.117598

Abstract

Introduction: There is increasing evidence that immunohistochemical expression of p53, Ki-67, and Bcl-2 is associated with aggressive (aBCC) and less aggressive (nBCC) histological subtypes and may have a prognostic role.

Aim: To investigate the clinicopathological features and immunohistochemical expressions of p53, Ki-67, and Bcl-2 in cutaneous basal cell carcinoma focusing on histological subtypes. Their roles and possible interactions in the development and progression of BCC are discussed.

Material and methods: A total of 50 BCC samples from 50 patients from Western Mexico between June 2018 and June 2019 were included. Paraffin-embedded samples were immunostained with p53, Ki-67, and Bcl-2 antibodies. Semi-quantitative analysis was performed to determine the intensity and positivity of immunostained cells. Parametrical and non-parametrical tests were performed according to the sample’s distribution.

Results: Samples included 21 nBCC and 29 aBCC. The statistical analysis showed statistical association when grouped as non-aggressive and aggressive subtypes for p53 (p = 0.04) and Bcl-2 (p < 0.01). An inverse negative correlation was found between age and Bcl-2 expression. No statistical association was found between Ki-67 immunoreactivity and any of the other variables.

Conclusions: We found that a high expression of Bcl-2 and a low expression of p53 was associated with more indolent histopathological features of BCC and therefore better outcomes. These findings suggest that examination of p53 and Bcl-2 expression in BCC patients may provide valuable prognostic information. These biomarkers may play a role in the development and progression of some cases of BCC.

Key words: Ki-67 antigen, tumour suppressor protein p53, prognosis, BCL2 protein, human, carcinoma, basal cell.

Introduction

Basal cell carcinoma (BCC) has a slow growth rate, minimal soft tissue invasiveness, and a high cure rate. Occasionally, BCC can behave aggressively, invading deep tissues, and potentially having metastatic behaviour. Nodular and superficial BCC subtypes are classically acknowledged as non-aggressive or less aggressive BCCs (nBCC), while more aggressive BCCs (aBCC) include the following patterns: metatypical, micronodular and infiltrative or morpheaform [1].

The association between the prognosis of solid tumours and the p53, Ki-67, and Bcl-2 biomarker expression has not been fully elucidated. The tumour suppressor p53 is the most frequently mutated gene in human cancers, and its inactivation is the second most frequent event following upregulation of the Hedgehog signalling pathway.
Advances in Dermatology and Allergology 3, June/2022

Bcl-2 was performed using automated staining with the expression was graded. Histopathologic examination

Histopathologic subtypes were re-confirmed and in tumours with mixed histological subtypes, the predominant component was recorded. Additional variables such as desmoplasia, Clark level, solar elastosis and pigment deposition were also evaluated. The haematoxylin-eosin stained sections of all samples were reviewed by two experienced pathologists (D.E.V) to determine the histological subtype and then immunohistochemistry examination for Ki-67 and p53 were evaluated. Only histological areas that presented the neoplasm were assessed. The staining intensity was classified from 0 to 3 (0 for negative staining, 1 for weak staining, 2 for moderate staining, and 3 for strong staining). Positivity was determined by observing all slides at low power (40×) and then randomly selecting three fields at high power (400×) to estimate an average percentage of immunolabelled positive cells. Disparities in percentages were solved by digital imaging analysis with QuPath software version 0.2.2 [10]. Percentage positivity was ranked from 0 to 4; 0 (no positive cells), 1 (< 10% of positive cells), 2 (10–50% of positive cells), 3 (51–80% of positive cells) and 4 (> 80% of positive cells). The sum of the ordinal scores for percentage and intensity of immunostaining allowed obtaining an expression score from 0 to 7, where 0–3 was considered as a low expression and 4–7 as a high expression.

Statistical analysis

The relationship between biomarker expression and the clinicopathological features were analysed using the Fisher’s exact test. Multinomial linear regression was conducted to recognize the association between the biomarkers ki-67, p53 and Bcl-2 and the rest of the variables. A correlation test was used to estimate the degree of association between variables. Statistical significance was considered with a value of \( p < 0.05 \). Data were analysed using IBM SPSS® statistics version 25 (Armonk, New York, USA).

Quality assessment

The Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) guidelines were used to evaluate manuscripts’ quality in order to enhance the possibilities of comparing results across studies involving molecular biomarkers [11].
Results

Clinico-pathological data

A total of 50 BCC samples from 50 patients were included, from June 2018 to June 2019. Clinicopathological results are shown in Table 1.

Biomarker expression

High expression of p53 was found in 30 (60%) samples and low expression in 20 (40%) samples. High expression of ki-67 was found in 33 (66%) samples and low expression in 17 (34%) samples. High expression of Bcl-2 was found in 24 (48%) samples and low expression in 26 (52%) samples.

The immunohistochemical patterns evaluated as low (0–3) and high (4–7) expressions between non-aggressive BCCs and aggressive BCCs are shown in Figure 1. Representative immunohistochemical expressions are shown in Figure 2.

Relationship and association of biomarker expression and clinicopathological variables

We observed a statistically significant association when BCCs were grouped as non-aggressive and aggressive subtypes for p53 (p = 0.04) and Bcl-2 (p < 0.01). No statistical association was found between Ki-67 and tumour aggressiveness. No statistical association was found between histological variables and biomarkers (Table 2).

Multinomial logistic regression analysis showed that the expression of Ki-67, p53 and Bcl-2 was statistically associated with the aggressiveness of the tumour. Compared with BCCs with low Bcl-2 expression, BCCs with high expression of Bcl-2 were obviously associated with a non-aggressive subtype (OR = 8.79; 95% CI: 3.21–61.9, p = 0.01). In addition, the odds ratio for associating a low expression of p53 (as compared to a high expression of p53) with a non-aggressive BCC was significant (OR = 6.4; 95% CI: 1.17–23.9, p = 0.006).

On the other hand, the probability of associating a high level of ki-67 (compared to a low level of ki-67) with a low aggressiveness was significant (OR = 2.96; 95% CI: 0.39–8.78, p = 0.05). Given that the latter value presents a borderline p-value, it should be taken with caution. There was no statistical significance with age, histological subtype, pigment deposition, desmoplasia or Clark level (Table 3).

Correlation between Bcl-2, p53, and Ki-67 expression and clinicopathological characteristics

A correlation test among biomarker expression and clinicopathological features was performed. Bcl-2 showed a significant negative correlation with age (correlation coefficient = −0.308, p ≤ 0.05) (Table 4).

Table 1. Clinical and histological characteristics (n = 50)

| Variable                      | BCC n (%) |
|-------------------------------|-----------|
| Age [years]                   | 67 ±15    |
| Gender:                       |           |
| Male                          | 20 (40)   |
| Female                        | 30 (60)   |
| Histological subtype:         |           |
| Nodular                       | 25 (50)   |
| Morpheaform                   | 10 (18)   |
| Micronodular                  | 10 (18)   |
| Adenoid                       | 4 (8)     |
| Metatypical                   | 2 (4)     |
| Solar elastosis:              |           |
| Present                       | 39 (78)   |
| Absent                        | 11 (22)   |
| Pigment deposition:           |           |
| Present                       | 24 (48)   |
| Absent                        | 26 (52)   |
| Clark level:                  |           |
| V                             | 5 (10)    |
| IV                            | 27 (54)   |
| III                           | 17 (34)   |
| II                            | 1 (2)     |
| I                             | 0 (0)     |
| Desmoplasia:                 |           |
| Severe                        | 7 (14)    |
| Moderate                      | 26 (52)   |
| Mild                          | 15 (30)   |
| Absent                        | 2 (4)     |

Table 4. Correlation coefficients and p-values

| Biomarker | Age | p-value |
|-----------|-----|---------|
| Bcl-2     | 0.05| 0.05    |
| P53       | 0.05| 0.05    |
| Ki-67     | 0.05| 0.05    |

Figure 1. Immunohistochemical expression patterns in aggressive and non-aggressive (less aggressive) groups
Figure 2. Representative images of immunohistochemical expression of p53 (B, F, J, N), Ki-67 (C, G, K, O) and Bcl-2 (D, H, L, P) in infiltrative morpheaform basal cell carcinoma (A), nodular basal cell carcinoma (E), adenoid basal cell carcinoma (I) and infiltrative morpheaform basal cell carcinoma (M). A, E, G, I, J, M, N, O – 40×, B, C, D, F, K, L – 100×, H – 400×

Table 2. Relationship of immunostaining results for aggressive and non-aggressive groups of BCCs

| Biomarker | Expression | Total | Non-aggressive BCCs | Aggressive BCCs | P-value* |
|-----------|------------|-------|----------------------|-----------------|----------|
| p53       | Low        | 20    | 15 (75)              | 5 (25)          | 0.04     |
|           | High       | 30    | 14 (46.6)            | 16 (53.4)       |          |
| Ki-67     | Low        | 17    | 10 (58.8)            | 7 (41.2)        | 0.93     |
|           | High       | 33    | 19 (57.5)            | 14 (42.5)       |          |
| Bcl-2     | Low        | 26    | 8 (30.7)             | 18 (69.3)       | < 0.01   |
|           | High       | 24    | 21 (87.5)            | 3 (12.5)        |          |

*P-value from the Fisher’s exact test.
Role of Bcl-2, p53, and Ki-67 expression in basal cell carcinoma and their association with aggressive and non-aggressive histological phenotypes

**Discussion**

BCC histological subtypes considered aggressive are particularly more complicated to treat due to subclinical extension, local destruction, and unfavourable biologic behaviour with higher recurrence rates. In addition, histologic subtypes of BCC that include morpheaform, micronodular, and metatypical patterns, are more likely to metastasize [12, 13].

Table 3. Multinomial logistic regression analysis

| Low BCL-2a  | \(B\) | Std. error | Wald | \(P\)-value | OR (odds ratio) | 95% confidence interval for OR |
|-------------|------|------------|------|-------------|----------------|--------------------------------|
| Low Ki-67   |      |            |      |             |                | Lower bound  | Upper bound  |
| Age         | –0.04| 0.027      | 2.20 | 0.13        | 0.96           | 0.91            | 1.01            |
| Histological subtype | –0.72| 0.69      | 1.09 | 0.29        | 0.48           | 0.13            | 1.87            |
| Sola elastosis | 1.44 | 1.14      | 1.6  | 0.21        | 4.2            | 0.45            | 36.02           |
| Pigment deposition | –0.57| 0.96      | 0.35 | 0.56        | 0.57           | 0.086           | 3.73            |
| Clark level  | –0.46| 0.68      | 0.47 | 0.49        | 0.63           | 0.16            | 2.39            |
| Desmoplasia | 0.61 | 0.57      | 0.65 | 0.42        | 1.84           | 0.42            | 8.16            |
| Aggressive BCCs | 1.08 | 0.66      | 2.68 | 0.101       | 2.93           | 0.81            | 10.6            |
| High Ki-67  |      |            |      |             |                | Lower bound  | Upper bound  |
| Age         | –0.007| 0.022   | 0.11 | 0.74        | 0.99           | 0.95            | 1.04            |
| Histological subtype | 0.29 | 0.51    | 0.33 | 0.57        | 1.34           | 0.49            | 3.65            |
| Sola elastosis | 0.49 | 0.94    | 0.27 | 0.60        | 1.63           | 0.26            | 10.39           |
| Pigment deposition | –0.25| 0.87   | 0.092 | 0.762  | 0.77          | 0.14            | 4.23            |
| Clark level  | 0.12 | 0.57    | 0.05 | 0.83        | 1.13           | 0.37            | 3.49            |
| Desmoplasia | –0.25| 0.584   | 0.18 | 0.67        | 0.78           | 0.25            | 2.46            |
| Aggressive BCCs | 1.08 | 0.55    | 3.8  | 0.05        | 2.96           | 0.39            | 8.78            |
| Low p53     |      |            |      |             |                | Lower bound  | Upper bound  |
| Age         | –0.026| 0.025 | 1.11 | 0.29        | 0.97           | 0.93            | 1.02            |
| Histological subtype | 0.145| 0.591   | 0.60 | 0.81        | 1.16           | 0.36            | 3.68            |
| Sola elastosis | 1.08 | 1.04    | 1.09 | 0.29        | 2.94           | 0.39            | 22.36           |
| Pigment deposition | –0.205| 0.95 | 0.047 | 0.83  | 0.82          | 0.13            | 5.23            |
| Clark level  | –0.43| 0.66    | 0.43 | 0.51        | 0.65           | 0.18            | 2.35            |
| Desmoplasia | –0.019| 0.65   | 0.001 | 0.97  | 0.98          | 0.274           | 3.52            |
| Aggressive BCCs | 1.86 | 0.67    | 7.6  | 0.006       | 6.4            | 1.17            | 23.9            |
| High p53    |      |            |      |             |                | Lower bound  | Upper bound  |
| Age         | –0.013| 0.022 | 0.357 | 0.550   | 0.98          | 0.94            | 1.03            |
| Histological subtype | –0.101| 0.52 | 0.037 | 0.85  | 0.90          | 0.32            | 2.52            |
| Sola elastosis | 0.44 | 0.99    | 0.19 | 0.66        | 1.55           | 0.22            | 10.89           |
| Pigment deposition | –0.67 | 0.88 | 0.58  | 0.45    | 0.51          | 0.09            | 2.86            |
| Clark level  | 0.13 | 0.58    | 0.05 | 0.82        | 1.14           | 0.37            | 3.56            |
| Desmoplasia | 0.105| 0.616   | 0.029 | 0.87  | 1.11          | 0.33            | 3.72            |
| Aggressive BCCs | 0.63 | 0.56    | 1.26 | 0.26        | 1.88           | 0.62            | 5.69            |
| High bc12   |      |            |      |             |                | Lower bound  | Upper bound  |
| Age         | –0.03 | 0.025   | 1.77 | 0.18        | 0.97           | 0.92            | 1.01            |
| Histological subtype | –0.07 | 0.59 | 0.016 | 0.89  | 0.93          | 0.29            | 2.93            |
| Sola elastosis | 1.43 | 1.02    | 1.98 | 0.16        | 4.19           | 0.57            | 30.7            |
| Pigment deposition | –0.68 | 0.92 | 0.56  | 0.46    | 0.51          | 0.08            | 3.04            |
| Clark level  | –0.298| 0.64 | 0.22  | 0.64    | 0.74          | 0.21            | 2.6             |
| Desmoplasia | 0.149| 0.66    | 0.05 | 0.82        | 1.17           | 0.321           | 4.48            |
| Aggressive BCCs | 2.64 | 0.76    | 12.3 | 0.01        | 8.79           | 3.21            | 61.9            |

*The reference category: \(R^2 = 0.244\) (Cox and Snell).*
Increased nuclear staining for mutant p53 reflects a loss of function of p53. In sporadic BCCs, inactivating mutations in the TP53 gene have been found in 50% of BCCs [14]. Our analysis of p53 expression revealed a statistical association with tumour aggressiveness. These findings are consistent with Oana et al. [15] who found that infiltrative BCCs had higher p53 expression in comparison to the nodular subtype (p = 0.054). Likewise, ShamsiMeymandi et al. [3] assessed p53 expression between aBCC and nBCC and found a significantly higher expression in the aggressive groups. In addition, Brito et al. [16] reported a higher expression in recurrent BCC and infiltrative BCC than the normal epidermis. Mutations of p53 may also have an impact on BCC treatment. A recent study of p53 expression found that cell lines that displayed mutations of p53 were more resistant to imiquimod-induced apoptosis [17]. Moreover, p53 expression was also associated with BCC resistance to photodynamic therapy (PDT) [18].

In our study, the number of tumour cells in BCC expressing Ki-67 antigen exhibited wide variation, and a high expression was found independent of the histological subtype. These findings are consistent with ShamsiMeymandi et al. [3] who evaluated an equivalent number of cases amongst most histological subtypes (n = 22 aBCCs vs. 20 nBCCs) and found no difference in Ki-67 expression. However, Khalesi et al. [19] evaluated nBCC and found a significantly higher expression of Ki-67 in the superficial subtype compared to the nodular subtype. Interestingly, Yerebakan et al. [20] found strong differences (p < 0.0001) of expression in recurrent tumours but not between histological subtypes.

Our results concerning Bcl-2 are consistent with previous data, where nBCC had a higher expression. Like our study, all following studies found a significant difference between the two groups, with the expression being the highest in nBCCs and lowest in aBCCs. Ramdial et al. [21] reported a low Bcl-2 expression in all of their aBCCs compared to nBCCs (p < 0.02). Zagrodnik et al. [22] examined recurrent tumours in patients treated with radiotherapy and found a significant correlation between low Bcl-2 expression and aBCCs (p = 0.0169) but not with recurrences. Sivrikoz et al. [9] included more samples of aBCCs (n = 77) than nBCC (n = 23). The contrast of Bcl-2 expression in aBCC and nBCC in our study suggests that they form a complex group of tumours that differ considerably in morphologic and biological behaviour, despite the common origin of these tumours from basal stem cells [23]. In the context of these previous studies, our findings suggest that a high expression of Bcl-2 might be a favourable prognosis factor. This can be explained by the finding that although Bcl-2 inhibits apoptosis it may also slow cell growth [24]. It is known that ultraviolet (UV) radiation induces downregulation of Bcl-2 in vivo and in vitro [25]. A recent study concluded that apoptosis in BCC does not involve BAX and that the apoptotic activity of BCCs is regulated by either less common members of the BCL2 gene family or a BCL2 gene family independent pathway [26]. The increase in genetic mutations induced by UV or other carcinogens together with a spontaneous or UV-induced downregulation of Bcl-2 may result in aggressive biological behaviour in BCCs. UV chronic exposure could explain our findings of the correlation between older age and lower Bcl-2 expression.

**Conclusions**

We have found that a high expression of Bcl-2 and a low p53 expression is associated with more indolent histopathological features with better outcomes. Our results suggest that analysis of p53 and Bcl-2 expression in BCC patients may provide useful prognostic information. However, the clinical implications of these interactions in BCC need to be critically evaluated.

**Acknowledgments**

Carlos Slim Foundation Health Scholarship for research, Mexico City. This foundation was not involved in study design, collection, analysis, or interpretation of data.

**Conflict of Interest**

The authors declare no conflict of interest.

**References**

1. Walling HW, Fosko SW, Geraminejad PA, et al. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev 2004; 23: 389-402.
2. Pellegrini C, Maturo MG, Di Nardo L, et al. Understanding the molecular genetics of basal cell carcinoma. Int J Mol Sci 2017; 18: 2485.

3. ShamsiMeymand S, Dabiri S, ZeynadiniMeymand A, et al. Evaluation of immunohistochemical findings and clinical features associated with local aggressiveness in basal cell carcinoma. Iran J Pathol 2019; 14: 193-6.

4. Luo Y, Ren F, Liu Y, et al. Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysis. Int J Clin Exp Med 2015; 8: 10235-47.

5. Richards-Taylor S, Ewings SM, Jaynes E, et al. The assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: a systematic review and meta-analysis. J Clin Pathol 2016; 69: 612-8.

6. Ramdial PK, Madaree A, Reddy R, et al. Bcl-2 protein expression in aggressive and non-aggressive basal cell carcinomas. J Cutan Pathol 2000; 27: 283-91.

7. Martinez-Arribas F, Alvarez T, Del Val G, et al. Bcl-2 expression in breast cancer: a comparative study at the mRNA and protein level. Anticancer Res 2007; 27: 219-22.

8. Feng C, Wu J, Yang F, et al. Expression of Bcl-2 is a favorable prognostic biomarker in lung squamous cell carcinoma. Oncol Lett 2018; 15: 6925-30.

9. Silvnikoz ON, Kandiloluğlu G. The effects of cyclin D1 and Bcl-2 expression on aggressive behavior in basal cell and basosquamous carcinoma. Iran J Pathol 2015; 10: 185-91.

10. Bankhead P, Loughrey MB, Fernández JA, et al. QuPath: open source software for digital pathology image analysis. Sci Rep 2017; 7: 16878.

11. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005; 93: 387-91.

12. Shih S, Dai C, Ansari A, et al. Metatypical basal cell carcinoma with intravascular invasion. Cureus 2018; 10: e3401.

13. Gąsiorowski K, Iwulska K, Zapała J, et al. Periocular basal cell carcinoma: recurrence risk factors/when to reoperate? Adv Dermatol Allergol 2020; 37: 927-31.

14. Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med 2015; 88: 167-79.

15. Oana A, Stepan AE, Margaritescu C, et al. Immunoexpression of p53 and COX-2 in basal cell carcinoma. Rom J Morphol Embryol 2019; 59: 1115-20.

16. Lima JSB, Miola AC, Marques MEA, et al. Patterns of proliferation and apoptosis in different subtypes of basal cell carcinoma, adjacent epidermis, and recurrent forms. An Bras Dermatol 2019; 94: 108-10.

17. Huang SW, Chang SH, Mu SW, et al. Imiquimod activates p53-dependent apoptosis in a human basal cell carcinoma cell line. J Dermatol Sci 2016; 81: 182-91.

18. Lucena SR, Zamarrón A, Carrasco E, et al. Characterisation of resistance mechanisms developed by basal cell carcinoma cells in response to repeated cycles of photodynamic therapy. Sci Rep 2019; 9: 4835.

19. Khalesi M, Waterhouse M, Whiteman DC, et al. Comparison of PTCH1, COX-2, P53 and Ki-67 protein expression in basal cell carcinomas of nodular and superficial subtypes arising on the head and trunk. Int J Dermatol 2016; 55: 1096-105.

20. Yerebakan O, Ciftcioglu MA, Akkaya BK, et al. Prognostic value of Ki-67, CD31 and epidermal growth factor receptor expression in basal cell carcinoma. J Dermatol 2003; 30: 33-41.